Family Medicine · Las Vegas, NV
NPI
1992232334
Since 2017
Specialty
Family Medicine
Code 207Q00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
8300 W Cheyenne Ave Ste 105
Las Vegas, NV, 89129
Phone (702) 656-0911
Groups this clinician bills Medicare through
Medicare paid, 2024
$2,792
58 services
Medicare patients, 2024
27
Average age 72
Drug cost, 2024
$2.7M
4,115 prescriptions
Company payments, 2025
$3,053
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mandeep Gill was code 99439 (chronic, principal, and transitional care management), 23 times for 12 patients. In total Mandeep Gill billed 58 services in 5 codes, and Medicare paid $2,792.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-07-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99439 Chronic, Principal, and Transitional Care Management | Office | 23 | 12 | $37.19 | $855 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 23 | 19 | $48.64 | $1,119 |
By year: 2022 $69K for 1,177 services; 2023 $67K for 1,799 services; 2024 $2,792 for 58 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 13 | 13 | $8.92 | $116 |
| 36415 Venipuncture Blood Collection | 12 | 12 | $8.40 | $101 |
Medicare prescription drug claims, 2024
In 2024, the drug Mandeep Gill prescribed most often to Medicare patients was Levothyroxine Sodium, with 338 prescriptions and refills. In total Mandeep Gill wrote 4,115 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 338 | 939 | 122 | $2,721 |
| Ozempic Semaglutide | 246 | 473 | 79 | $452K |
| Glimepiride Generic | 218 | 639 | 70 | $2,009 |
| Metformin Hcl Generic | 199 | 587 | 80 | $1,433 |
| Metformin Hcl Er Metformin Hcl | 173 | 508 | 68 | $1,551 |
| Jardiance Empagliflozin | 159 | 402 | 56 | $231K |
| Pioglitazone Hcl Generic | 149 | 446 | 52 | $1,716 |
| Gvoke Hypopen 2-Pack Glucagon | 146 | 204 | 87 | $122K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 120 | 332 | 54 | $15K |
| Trulicity Dulaglutide | 120 | 200 | 34 | $193K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 113 | 312 | 57 | $30K |
| Mounjaro Tirzepatide | 100 | 167 | 27 | $174K |
| Xigduo Xr Dapaglifloz Propaned/Metformin | 99 | 191 | 24 | $100K |
| Farxiga Dapagliflozin Propanediol | 91 | 217 | 32 | $117K |
| Synthroid Levothyroxine Sodium | 85 | 224 | 27 | $8,042 |
Brand drugs: 2,206 claims; generic drugs: 1,688 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mandeep Gill $3,053 ($3,053 in general payments such as food, travel and fees) from 30 companies. The largest payer was Abbott Laboratories with $487.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 7 | $487 |
| Neurocrine BioSciences, Inc. NBIX | 9 | $266 |
| Xeris Pharmaceuticals, Inc. | 14 | $244 |
| Novo Nordisk Inc NVO | 8 | $206 |
| Recordati_rare_diseases_inc. | 10 | $201 |
| Abbvie Inc. ABBV | 13 | $198 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 27 | $185 |
| Amgen Inc. AMGN | 14 | $172 |
| Radius Health, Inc. | 8 | $161 |
| Lilly USA, LLC LLY | 6 | $110 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.